Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019August 16, 2022 Alterity Therapeutics

Chairman’s Address to Shareholders 2019 AGM

2019

Post navigation

AGM 2019 Presentation

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Related Posts

Results of General Meeting

April 5, 2019August 16, 2022

Prana AGM Webcast Details

November 10, 2015August 16, 2022

Alterity Half Year Results and Investor Webcast Notification

February 19, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065